Measurement of the time-temperature dependent dynamic mechanical properties of boron/aluminum composites

A flexural vibration test and associated equipment were developed to accurately measure the low strain dynamic modulus and damping of composite materials from -200 C to over 500 C. The basic test method involves the forced vibration of composite bars at their resonant free-free flexural modes in a high vacuum cryostat furnace. The accuracy of these expressions and the flexural test was verified by dynamic moduli and damping capacity measurements on 50 fiber volume percent boron/aluminum (B/Al) composites vibrating near 2000 Hz. The phase results were summarized to permit predictions of the B/Al dynamic behavior as a function of frequency, temperature, and fiber volume fraction

High temperature dynamic modulus and damping of aluminum and titanium matrix composites

Dynamic modulus and damping capacity property data were measured from 20 to over 500 C for unidirectional B/Al (1100), B/Al (6061), B/SiC/Al (6061), Al2O3/Al, SiC/Ti-6Al-4V, and SiC/Ti composites. The measurements were made under vacuum by the forced vibration of composite bars at free-free flexural resonance near 2000 Hz and at amplitudes below 0.000001. Whereas little variation was observed in the dynamic moduli of specimens with approximately the same fiber content (50 percent), the damping of B/Al composites was found at all temperatures to be significantly greater than the damping of the Al2O3/Al and SiC/Ti composites. For those few situations where slight deviations from theory were observed, the dynamic data were examined for information concerning microstructural changes induced by composite fabrication and thermal treatment. The 270 C damping peak observed in B/Al (6061) composites after heat treatment above 460 C appears to be the result of a change in the 6061 aluminum alloy microstructure induced by interaction with the boron fibers. The growth characteristics of the damping peak suggest its possible value for monitoring fiber strength degration caused by excess thermal treatment during B/Al (6061) fabrication and use

Thermal degradation of the tensile strength of unidirectional boron/aluminum composites

The variation of ultimate tensile strength with thermal treatment of B-Al composite materials and of boron fibers chemically removed from these composites in an attempt to determine the mechanism of the resulting strength degradation was studied. Findings indicate that thermally cycling B-Al represents a more severe condition than equivalent time at temperature. Degradation of composite tensile strength from about 1.3 GN/m squared to as low as 0.34 GN/m squared was observed after 3,000 cycles to 420 C for 203 micrometers B-1100 Al composite. In general, the 1100 Al matrix composites degraded somewhat more than the 6061 matrix material studied. Measurement of fiber strengths confirmed a composite strength loss due to the degradation of fiber strength. Microscopy indicated a highly flawed fiber surface

Thermal environment effects on strength and impact properties of boron-aluminum composites

Thermal effects on fracture strength and impact energy were studied in 50 volume percent unidirectional composites of 143 and 203 micron boron fibers in 6061 and 1100 aluminum matrices. For 6061 matrix composites, strength was maintained to approximately 400 C in the cyclic tests and higher than 400 C in the static tests. For the 1100 matrix composites, strength degradation appeared near 260 C after cycling and higher than 260 C in static heating. This composite strength degradation is explained by a fiber degradation mechanism resulting from a boron-aluminum interface reaction. The impact energy absorption degraded significantly only above 400 C for both matrix alloys. Thus, while impact loss for the 6061 composite correlates with the fiber strength loss, other energy absorption processes appear to extend the impact resistance of the 1100 matrix composites to temperatures beyond where its strength is degraded. Interrupted impact tests on as-received and thermally cycled composites define the range of load over which the fibers break in the impact event

Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis

Introduction: The incidence of death among patients admitted for severe sepsis or septic shock is high. Adrenomedullin (ADM) plays a central role in initiating the hyperdynamic response during the early stages of sepsis. Pilot studies indicate an association of plasma ADM with the severity of the disease. In the present study we utilized a novel sandwich immunoassay of bioactive plasma ADM in patients hospitalized with sepsis in order to assess the clinical utility.Methods: We enrolled 101 consecutive patients admitted to the emergency department with suspected sepsis in this study. Sepsis was defined by fulfillment of at least two systemic inflammatory response syndrome (SIRS) criteria plus clinical suspicion of infection. Plasma samples for ADM measurement were obtained on admission and for the next four days. The 28-day mortality rate was recorded.Results: ADM at admission was associated with severity of disease (correlation with Acute Physiology and Chronic Health Evaluation II (APACHE II) score: r = 0.46; P <0.0001). ADM was also associated with 28-day mortality (ADM median (IQR): survivors: 50 (31 to 77) pg/mL; non-survivors: 84 (48 to 232) pg/mL; P <0.001) and was independent from and additive to APACHE II (P = 0.02). Cox regression analysis revealed an additive value of serial measurement of ADM over baseline assessment for prediction of 28-day mortality (P < 0.01). ADM was negatively correlated with mean arterial pressure (r = -0.39; P <0.0001), and it strongly discriminated those patients requiring vasopressor therapy from the others (ADM median (IQR): no vasopressors 48 (32 to 75) pg/mL; with vasopressors 129 (83 to 264) pg/mL, P <0.0001).Conclusions: In patients admitted with sepsis, severe sepsis or septic shock plasma ADM is strongly associated with severity of disease, vasopressor requirement and 28-day mortality

Wind-tunnel tests of the XV-15 tilt rotor aircraft

The XV-15 aircraft was tested in the Ames 40 by 80 Foot Wind Tunnel for preliminary evaluation of aerodynamic and aeroelastic characteristics prior to flight. The tests were undertaken to investigate the aircraft performance, stability, control and structural loads for flight modes from helicopter through transition and airplane mode up to the tunnel capability of 170 knots. Results from these tests are presented

The Collaborative Development of New CFD Methods Adapted for Tilt Rotor Aircraft in the HiPerTilt Project

No abstract available

Depressive symptoms in asymptomatic stage B heart failure with Type II diabetic mellitus.

BackgroundThe presence of concomitant Type II diabetic mellitus (T2DM) and depressive symptoms adversely affects individuals with symptomatic heart failure (HF).HypothesisIn presymptomatic stage B HF, this study hypothesized the presence of greater inflammation and depressive symptoms in T2DM as compared to non-T2DM Stage B patients.MethodsThis cross-sectional study examined clinical parameters, inflammatory biomarkers, and depressive symptoms in 349 T2DM and non-T2DM men with asymptomatic stage B HF (mean age 66.4 years ±10.1; range 30-91).ResultsFewer diabetic HF patients had left ventricular (LV) systolic dysfunction (P < .05) although more had LV diastolic dysfunction (P < .001). A higher percentage of T2DM HF patients were taking ACE-inhibitors, beta-blockers, calcium channel blockers, statins, and diuretics (P values < .05). T2DM HF patients had higher circulating levels of interleukin-6 (IL-6) (P < .01), tumor necrosis factor-alpha (P < .01), and soluble ST2 (sST2) (P < .01) and reported more somatic/affective depressive symptoms (Beck Depression Inventory II) (P < .05) but not cognitive/affective depressive symptoms (P = .20). Among all patients, in a multiple regression analysis predicting presence of somatic/affective depressive symptoms, sST2 (P = .026), IL-6 (P = .010), B-type natriuretic peptide (P = .016), and sleep (Pittsburgh Sleep Quality Index [P < .001]) were significant predictors (overall model F = 15.39, P < .001, adjusted R2 = .207).ConclusionsSomatic/affective but not cognitive/affective depressive symptoms are elevated in asymptomatic HF patients with T2DM patients. Linkages with elevated inflammatory and cardiac relevant biomarkers suggest shared pathophysiological mechanisms among T2DM HF patients with somatic depression, and these conditions are responsive to routine interventions, including behavioral. Copyright © 2019 John Wiley & Sons, Ltd